Nivolumab + ipilimumab (melanoma)
Checked 2026-09-09
Unresectable or metastatic melanoma, especially with brain metastases or PD-L1-negative disease
One cycle
every 21 days × 4 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Ipilimumab Monoclonal antibody (anti-CTLA-4) | 3 mg/kg | IV | D1 | |
Nivolumab Monoclonal antibody (anti-PD-1) | 1 mg/kg | IV | D1 |
Cycles
4 combination, then nivolumab 480 mg every 4 weeks up to 2 years
21-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Grade 3-4 immune-related events in about 59%; the flipped-dose (nivolumab 3 mg/kg + ipilimumab 1 mg/kg, CheckMate 511) is less toxic.
Used in
Products
Source
CheckMate 067, NEJM 2015; 10-year update NEJM 2025
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Pembrolizumab monotherapy
Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)
every 21 days
Dabrafenib + trametinib
BRAF V600-mutant melanoma (adjuvant 1 year or metastatic), NSCLC, anaplastic thyroid cancer and tumour-agnostic use
every 28 days
Nivolumab + relatlimab
Unresectable or metastatic melanoma, first line
every 28 days